Although no systematic evaluation has been performed, the
GUSTO-I trial observed no intraocular haemorrhages in 6011
patients with diabetes. Currently, therefore, diabetic retinopathy is
only considered a contraindication to thrombolysis if there is clear
evidence of recent retinal haemorrhage.
FFuurrtthheerr rreeaaddiinngg
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications
for fibrinolytic therapy in suspected acute myocardial infarction:
collaborative overview of early mortality and major morbidity results
from all randomised trials of more than 1000 patients. Lancet1994; 334433 :
311–22.
Gunnar RM, Passamani ER, Bourdillon PDV et al. Guidelines for the
early management of patients with acute myocardial infarction. A report
of the American College of Cardiology/American Heart Association task
force on assessment of diagnostic and therapeutic cardiovascular
procedures. J Am Coll Cardiol1990; 1166 : 249–292.
Mahaffey KW, Granger CB, Toth CA et al. for the GUSTO-I Investigators.
Diabetic retinopathy should not be a contraindication for thrombolytic
therapy for acute myocardial infarction: review of ocular hemorrhage
incidence and location in the GUSTO-I trial. J Am Coll Cardiol1997; 3300 :
1606–10.
Ryan TJ, Anderson JL, Antman EM et al. ACC/AHA guidelines for the
management of patients with acute myocardial infarction. J Am Coll
Cardiol1996; 2288 : 1328–1428.
Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS.
Bleeding during thrombolytic therapy for acute myocardial infarction:
mechanisms and management. Ann Intern Med1989; 111111 : 1010–22.